These findings are in line with data from Shi and colleagues, indicating a lack of PARP and Caspase 3 cleavage in malignant pleural mesothelioma cells upon treatment with the SMO inhibitor HhAntag [10]. Here, CASP3 is linked to malignant pleural mesothelioma.